CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Fortress Biotech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Fortress Biotech Inc
1111 KANE CONCOURSE, SUITE 301
Phone: (781) 652-4500p:781 652-4500 BAY HARBOR ISLANDS, FL  33154  United States Ticker: FBIOFBIO
Business Summary
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Ra2 CAR T Cell Program for Glioblastoma), and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, President, Chief Executive Officer Lindsay A.Rosenwald 69 12/19/2013 10/1/2009
Chief Financial Officer and Head of Corporate Development DavidJin 34 8/16/2022 8/16/2022
Executive Vice Chairman - Strategic Development, Director Michael S.Weiss 58 2/1/2014 12/19/2013
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Journey Medical Corp 9237 E Via De Ventura Blvd. SCOTTSDALE AZ United States
Avenue Therapeutics Inc 1111 KANE CONCOURSE, SUITE 301 BAY HARBOR ISLANDS FL United States
Checkpoint Therapeutics Inc 95 SAWYER ROAD, SUITE 110 WALTHAM MA United States
3 additional Subsidiary records available in full report.

Business Names
Business Name
Aevitas Therapeutics, Inc.
Avenue Therapeutics, Inc.
Baergic Bio, Inc.
16 additional Business Names available in full report.

General Information
Number of Employees: 101 (As of 12/31/2024)
Outstanding Shares: 29,533,840 (As of 3/27/2025)
Shareholders: 394
Stock Exchange: NASD
Federal Tax Id: 205157386
Fax Number: (781) 652-4545
Email Address: info@coronadobio.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025